These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 6310815

  • 1. Prostaglandin H2 directly lowers human platelet cAMP levels.
    Rybicki JP, Le Breton GC.
    Thromb Res; 1983 Jun 01; 30(5):407-14. PubMed ID: 6310815
    [Abstract] [Full Text] [Related]

  • 2. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
    Brace LD, Venton DL, Le Breton GC.
    Am J Physiol; 1985 Jul 01; 249(1 Pt 2):H1-7. PubMed ID: 3925795
    [Abstract] [Full Text] [Related]

  • 3. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
    Brace LD, Venton DL, Le Breton GC.
    Am J Physiol; 1985 Jul 01; 249(1 Pt 2):H8-13. PubMed ID: 2409821
    [Abstract] [Full Text] [Related]

  • 4. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB, Patscheke H.
    Prog Clin Biol Res; 1989 Jul 01; 301():315-9. PubMed ID: 2798452
    [Abstract] [Full Text] [Related]

  • 5. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
    Kuzuya T, Hoshida S, Yamagishi M, Ohmori M, Inoue M, Kamada T, Tada M.
    Jpn Circ J; 1986 Nov 01; 50(11):1071-8. PubMed ID: 3102802
    [Abstract] [Full Text] [Related]

  • 6. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA, Jones RL, Peesapati V, Will SG, Wilson NH.
    Br J Pharmacol; 1985 Mar 01; 84(3):595-607. PubMed ID: 2580580
    [Abstract] [Full Text] [Related]

  • 7. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
    Gorman RR, Fitzpatrick FA, Miller OV.
    Biochem Biophys Res Commun; 1977 Nov 07; 79(1):305-13. PubMed ID: 200243
    [No Abstract] [Full Text] [Related]

  • 8. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
    Mevkh AT, Basevich VV, Varfolomeev SD.
    Biokhimiia; 1984 Dec 07; 49(12):2035-40. PubMed ID: 6441604
    [Abstract] [Full Text] [Related]

  • 9. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1984 Jan 07; 228(1):240-4. PubMed ID: 6319669
    [Abstract] [Full Text] [Related]

  • 10. The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets.
    Mayeux PR, Morton HE, Gillard J, Lord A, Morinelli TA, Boehm A, Mais DE, Halushka PV.
    Biochem Biophys Res Commun; 1988 Dec 15; 157(2):733-9. PubMed ID: 2974286
    [Abstract] [Full Text] [Related]

  • 11. Platelet interaction with vascular smooth muscle in synthesis of prostacyclin.
    Hechtman DH, Kroll MH, Gimbrone MA, Schafer AI.
    Am J Physiol; 1991 May 15; 260(5 Pt 2):H1544-51. PubMed ID: 1903602
    [Abstract] [Full Text] [Related]

  • 12. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
    Hornberger W, Patscheke H.
    Eicosanoids; 1989 May 15; 2(4):241-8. PubMed ID: 2517034
    [Abstract] [Full Text] [Related]

  • 13. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
    Hanasaki K, Arita H.
    Biochem Pharmacol; 1988 Oct 15; 37(20):3923-9. PubMed ID: 2973322
    [Abstract] [Full Text] [Related]

  • 14. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
    Le Breton GC, Lipowski JP, Feinberg H, Venton DL, Ho T, Wu KK.
    J Pharmacol Exp Ther; 1984 Apr 15; 229(1):80-4. PubMed ID: 6423815
    [Abstract] [Full Text] [Related]

  • 15. Endothelium-dependent and independent responses to prostaglandin H2 and arachidonic acid in isolated dog cerebral arteries.
    Toda N, Inoue S, Bian K, Okamura T.
    J Pharmacol Exp Ther; 1988 Jan 15; 244(1):297-302. PubMed ID: 3121847
    [Abstract] [Full Text] [Related]

  • 16. Evidence for a bidirectional prostaglandin endoperoxide shunt between platelets and the bovine coronary artery.
    Mayeux PR, Kadowitz PJ, McNamara DB.
    Biochim Biophys Acta; 1989 Mar 28; 1011(1):18-24. PubMed ID: 2493809
    [Abstract] [Full Text] [Related]

  • 17. Characterization of thromboxane receptors in human platelets.
    Jones RL, Wilson NH, Armstrong RA.
    Adv Exp Med Biol; 1985 Mar 28; 192():67-81. PubMed ID: 3010674
    [No Abstract] [Full Text] [Related]

  • 18. Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.
    Dorn GW, Burch RM, Kochel PJ, Mais DE, Halushka PV.
    Biochem Pharmacol; 1987 Jun 15; 36(12):1913-7. PubMed ID: 2954555
    [Abstract] [Full Text] [Related]

  • 19. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1982 Jul 15; 222(1):276-81. PubMed ID: 7086705
    [Abstract] [Full Text] [Related]

  • 20. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R, Mezzasoma AM, Venditti G, Gresele P.
    Thromb Haemost; 2002 Jan 15; 87(1):114-21. PubMed ID: 11848439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.